Beyond Hit Identification: How End-to-End Protein Science Accelerates Molecular Glue Discovery

Molecular glues are reshaping targeted protein degradation (TPD) by offering a compact, drug-like alternative to bifunctional degraders. These small molecules work by inducing or stabilizing a productive interaction between a target protein and an E3 ligase complex – triggering selective degradation of disease-relevant proteins.

But molecular glue discovery comes with a catch. Unlike traditional inhibitors, a genuine molecular glue may show no measurable affinity for one of its protein partners when tested in isolation. Productive ternary complexes can emerge from binary interactions that appear weak or undetectable, making it difficult to separate a truly cooperative glue from an unproductive screening hit.

For drug discovery teams, this creates a high-stakes decision point: how do you confirm a true molecular glue mechanism before committing medicinal chemistry resources?

An Integrated Workflow to Answer the Right Questions Early

At Eurofins Discovery, our Protein Science teams address this challenge through a single, end-to-end workflow that combines drug discovery–grade recombinant protein development, quantitative biophysical characterization and cryo-electron microscopy (cryo-EM) structural analysis.

A recent case study using WEE1 kinase and the CRBN:DDB1 E3 ligase complex illustrates how this end-to-end approach works in practice.

Building a Solid Foundation: High-Quality Protein Reagents

Reliable characterization starts with reliable reagents. The study generated highly purified (>97%), monodisperse preparations of both WEE1 and CRBN:DDB1, confirmed by orthogonal quality controls including dynamic light scattering (DLS) and thermal stability profiling (nanoDSF). This level of protein quality is essential: sample heterogeneity or aggregation can introduce artifacts that compromise both biophysical measurements and cryo-EM data downstream.

Spectral Shift Assays: The Cooperative Glue Signature

With protein quality established, Spectral Shift assays were used to directly compare binary and ternary binding within the same experimental framework.

Results told a clear story:

• No detectable interaction between the compound and WEE1 alone (K_D > 30 µM)
• Nanomolar affinity for CRBN in binary mode
• Strong ternary complex formation when both proteins were present: K_D = 339 nM, cooperativity factor (α) > 88

This pronounced affinity enhancement upon addition of the second protein partner is the hallmark of a molecular glue mechanism, clearly distinguishing the compound from a conventional binary binder or a bifunctional degrader profile.

Cryo-EM: From Confirmation to Optimization

Biophysical methods establish molecular glue activity, whereas Cryo-EM visualizes the induced protein-protein interface and informs optimization strategies.

FIGURE 2: High-resolution 3D EM volume and model of the ternary complex (WEE1 in orange, CRBN in light blue, DDB1 in dark blue, molecular glue in purple). Caption: The cryo-EM reconstruction at 3.5 Å resolution reveals the architecture of the glue-induced ternary assembly.

The 3.5 Å cryo-EM structure of the WEE1–EDMG000103–CRBN:DDB1 complex revealed how the molecular glue drives WEE1 recruitment into the CRBN tri-tryptophan pocket, forming a composite interface that only exists upon ternary complex assembly. Key WEE1 G-loop residues, Gly322, Val317, and Asp321, were directly visualized at the recruitment interface, independently validating the G-loop degron mechanism described in the literature.

Critically for medicinal chemistry, the structure highlighted Val317 as a hydrophobic contact point unique to the WEE1 interface and absent from the equivalent CK1α surface therefore offering a concrete, residue-level vector for improving degrader selectivity.

Why This Matters for Discovery Leaders

Advancing a molecular glue program without robust ternary complex characterization is a gamble. Teams risk investing months of medicinal chemistry on compounds whose mechanism remains ambiguous, or missing genuinely cooperative hits that don’t conform to traditional binding profiles.

By frontloading protein quality, quantitative biophysics, and structural investigation within a single workflow, this integrated approach transforms a promising but uncertain hit into a well-understood starting point for optimization, with a clear structural rationale to guide the next round of chemistry.

As molecular glue programs move toward increasingly challenging targets and stringent selectivity requirements, this combination of quantitative biophysics and near-atomic structural visualization provides a decisive advantage in accelerating the path from hit to development candidate.

---

Explore Eurofins Discovery’s Protein Science solutions → Discover our capabilities | Talk to our experts

---